Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 4:22 pm Sale | 13G | Karyopharm Therapeutics Inc. KPTI | Avidity Partners Management LP | 4,741,060 3.700% | -6,447,683 (-57.63%) | View |
| 2024-11-12 3:50 pm Unchanged | 13G | Karyopharm Therapeutics Inc. KPTI | VANGUARD GROUP INC | 7,654,482 6.130% | 0 (Unchanged) | View |
| 2024-11-04 11:49 am Sale | 13G | Karyopharm Therapeutics Inc. KPTI | VANGUARD GROUP INC | 7,654,482 6.130% | -1,055,676 (-12.12%) | View |
| 2024-10-25 09:30 am Purchase | 13G | Karyopharm Therapeutics Inc. KPTI | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 9,744,885 7.200% | 9,744,885 (New Position) | View |
| 2024-07-08 4:32 pm Sale | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 4,169,788 3.500% | -5,901,889 (-58.60%) | View |
| 2024-05-23 4:30 pm Purchase | 13G | Karyopharm Therapeutics Inc. KPTI | J. WOOD CAPITAL ADVISORS LLC | 6,872,027 5.500% | 6,872,027 (New Position) | View |
| 2024-02-14 4:52 pm Sale | 13G | Karyopharm Therapeutics Inc. KPTI | Palo Alto Investors LP | 5,102,193 4.450% | -553,483 (-9.79%) | View |
| 2024-02-14 10:33 am Sale | 13G | Karyopharm Therapeutics Inc. KPTI | Avidity Partners Management LP | 11,188,743 9.500% | -192,330 (-1.69%) | View |
| 2024-02-13 5:07 pm Purchase | 13G | Karyopharm Therapeutics Inc. KPTI | VANGUARD GROUP INC | 8,710,158 7.600% | 8,710,158 (New Position) | View |
| 2024-02-12 06:06 am Sale | 13G | Karyopharm Therapeutics Inc. KPTI | Rubric Capital Management LP | 0 0.000% | -8,294,621 (Position Closed) | View |
| 2024-01-25 1:48 pm Purchase | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 10,071,677 8.800% | 1,563,440 (+18.38%) | View |
| 2024-01-22 1:50 pm Sale | 13G | Karyopharm Therapeutics Inc. KPTI | STATE STREET CORP STT | 2,053,773 1.790% | -158,594 (-7.17%) | View |
| 2023-07-10 2:26 pm Sale | 13G | Karyopharm Therapeutics Inc. KPTI | STATE STREET CORP STT | 2,212,367 1.940% | -6,074,669 (-73.30%) | View |
| 2023-02-14 4:21 pm Purchase | 13G | Karyopharm Therapeutics Inc. KPTI | Palo Alto Investors LP | 5,655,676 5.000% | 185,224 (+3.39%) | View |
| 2023-02-14 4:06 pm Sale | 13G | Karyopharm Therapeutics Inc. KPTI | COMMODORE CAPITAL LP | 1,935,609 1.700% | -2,075,443 (-51.74%) | View |
| 2023-02-14 3:41 pm Sale | 13G | Karyopharm Therapeutics Inc. KPTI | Chione Ltd | 4,400,000 3.900% | -600,000 (-12.00%) | View |
| 2023-02-14 3:31 pm Purchase | 13G | Karyopharm Therapeutics Inc. KPTI | Avidity Partners Management LP | 11,381,073 9.900% | 29,254 (+0.26%) | View |
| 2023-02-10 4:00 pm Purchase | 13G | Karyopharm Therapeutics Inc. KPTI | Rubric Capital Management LP | 8,294,621 7.330% | 8,294,621 (New Position) | View |
| 2023-02-02 12:38 pm Purchase | 13G | Karyopharm Therapeutics Inc. KPTI | STATE STREET CORP STT | 8,287,036 7.320% | 2,773,356 (+50.30%) | View |
| 2023-01-26 08:52 am Unchanged | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 8,508,237 10.500% | 0 (Unchanged) | View |